Background
Dyslipidaemia in HIV has been linked with both a cytokine-driven lipid metabolism re-arrangement in significant viraemia, and with the use of highly-active antiretroviral therapy (HAART), especially protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Methods
This study was a retrospective review, evaluating the efficacy and safety of Ezetimibe in our cohort of HIV-positive patients stable on HAART with dyslipidaemia. Out of the 29 such individuals prescribed 10 mg Ezetimibe once daily, 17 received it in addition to a statin, and 12 received it as a direct replacement for a statin.
Summary of results
Prior to initiation of Ezetimibe, median serum total cholesterol and triglyceride levels were 6.3 mmol/l (range: 3.6-10.7) and 2.9 mmol/l (range: 0.54-13.02), respectively. Review of the lipid profiles of the cohort after 12 weeks of Ezetimibe therapy revealed (see data in Figure 1 ). Two individuals discontinued Ezetimibe prematurely.
Conclusion
These results suggest that Ezetimibe may have an important role as an effective therapy for HAART-induced dyslipidaemia.
